John C Byrd

45PUBLICATIONS
192CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsOral medicine and pathologyHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Feb 03, 2026
Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Joshua F Zeidner, Jayanshu Jain, Rina Li Welkie

|Jan 21, 2026
DDX41-Mutated AML: A Case Report and Perspectives.

William M Yashar, Christopher A Eide, Stephen E Kurtz

|Jul 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung

|Jun 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann, Ronan Swords, Ying Huang

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

Pageof 8

Frequent Collaborators

10 joint publications

Jeffrey W Tyner

10 joint publications

Alice S Mims

10 joint publications

Shannon McWeeney

8 joint publications

Christopher A Eide